Curis | CRIS - Ebitda

Stock Price
0.74
Daily Change
0.11 17.75%
Monthly
-14.26%
Yearly
-42.98%
Q2 Forecast
0.49

Curis reported $-12.3M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bayer EUR 1.97B 457M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
CSL USD 3.13B 1.17B Dec/2025
Curis USD -12.3M 231K Sep/2023
Eli Lilly USD 7.88B 378.1M Sep/2025
Exelixis USD 248.93M 28.02M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 4.77B 1.11B Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025
TG Therapeutics USD 32.69M 5M Sep/2025
Xoma USD 2.52M 7.98M Jun/2024